Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Oncotarget|October 20, 2018
Estrogen receptor-beta is a potential target for triple negative breast cancer treatmentDavid Austin, Nalo Hamilton, Yahya Elshimali, et al.Journal of Medical Case Reports|December 4, 2016
Possible failure of novel direct-acting oral anticoagulants in management of pulmonary embolism: a case reportJames Rankin, Menachem Nagar, Jonathan Crosby, et al.Journal of the National Cancer Institute|May 20, 2004
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancerMark D Pegram, Gottfried E Konecny, Carminda O'Callaghan, et al.International Journal of Molecular Sciences|March 13, 2024
Correction: Hamilton et al. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int. J. Mol. Sci. 2017, 18, 2305Nalo Hamilton, David Austin, Diana Márquez-Garbán, et al.International Journal of Molecular Sciences|November 4, 2017
Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast CancerNalo Hamilton, David Austin, Diana Márquez-Garbán, et al.Therapeutic Advances in Medical Oncology|August 14, 2023
Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancerMark Pegram, Richard Pietras, Chau T Dang, et al.Critical Reviews in Oncogenesis|June 10, 2016
Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast CancerNalo Hamilton, Diana Marquez-Garban, Vei H Mah, et al.Biomed Research International|April 16, 2015
Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancerNalo Hamilton, Diana Márquez-Garbán, Vei Mah, et al.Breast Cancer Research and Treatment|March 25, 2017
A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cellsYanyuan Wu, Trinh Tran, Sami Dwabe, et al.Molecular Imaging and Biology|December 20, 2005
Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapyBetty S Pio, Cecilia K Park, Richard Pietras, et al.Pageof 2